Inhibrx Biosciences, Inc. has made headlines with the announcement of updated clinical data for its investigational drug ozekibart (INBRX-109). The data, which shows a 62.7% overall response rate in patients with relapsed or refractory Ewing sarcoma, was released on November 17, 2026, and will be presented at the upcoming Connective Tissue Oncology Society Annual Meeting.

This development is significant as it underscores Inhibrx's ongoing efforts to innovate within the biopharmaceutical landscape, particularly in the treatment of rare cancers. The promising results may provide new hope for patients who have limited treatment options.

Background

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates. The company operates within the Biological Products (No Diagnostic Substances) sector, as classified under the SIC code 2836. Inhibrx is publicly traded on the Nasdaq under the ticker symbol INBX.

Recent filings from Inhibrx include a Schedule 13G/A and a Form S-3ASR, both filed on November 13, 2026, along with a 10-Q report. The company has been actively engaging with the market and investors, showcasing its commitment to transparency and growth.

What the Filing Says

The SEC filing details that on November 17, 2026, Inhibrx announced the updated clinical data from its Phase 1/2 expansion study evaluating ozekibart in combination with irinotecan and temozolomide for Ewing sarcoma patients. The press release highlighted a 62.7% overall response rate and an 86.3% disease control rate, indicating significant efficacy in a challenging patient population.

Mark Lappe, CEO of Inhibrx, stated, "The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas." He emphasized the importance of these results in providing new treatment avenues for patients who have exhausted other options.

Impact

The updated clinical data from Inhibrx may significantly impact patients with relapsed or refractory Ewing sarcoma, a rare and aggressive cancer. With approximately 300 new cases diagnosed annually in the U.S., the need for effective treatments is critical. The findings could also influence the broader oncology market, as they demonstrate the potential for innovative therapies to improve patient outcomes.

What's Next

Following this announcement, Inhibrx plans to advance its development plans for ozekibart with the goal of providing patients access to this promising therapy as soon as possible. The filing does not specify any upcoming votes or additional filings related to this announcement.

For more information, the full text of the press release is attached as Exhibit 99.1 to the SEC filing (accession number 0002007919-26-000063).